Story perspectives
Debate Erupts Over Medicare's Drug Price Negotiation Law
8/9/2025
32 4
1 of 1
Story summary
- The Inflation Reduction Act of 2022 empowers Medicare to negotiate drug prices, igniting fierce debate over its constitutionality. Critics, including pharmaceutical giants like Boehringer Ingelheim, argue this stifles innovation and infringes on rights. However, the Second Circuit judges defended the law, emphasizing that participation is voluntary, albeit with hefty penalties for those who opt out.
